期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

A33抗原表达调控机制及其抗体导向肿瘤放射免疫治疗

Mechanism of A33' Tissue-Specific Expression and A33-Induced Radioimmunotherapy
原文传递
导出
摘要 人肠上皮细胞表面抗原A33是一种在人胃肠道上皮细胞特异性表达的跨膜糖蛋白,在95%以上的大肠癌、63%的胃癌和50%的胰腺癌中表达,而在其它组织或其它肿瘤细胞中鲜有表达。近年来就A33的组织特异性表达模式进行了深入的研究,揭示了与A33的特异性表达相关的特异性启动子和组织特异性转录因子(GKLF、CDX1)。A33抗体导向下的直肠癌放射免疫治疗已成为单克隆抗体(monoc lonal an-tibody,MCAB)导向治疗研究领域的热点,且已经进入Ⅰ期放射免疫治疗临床实验。 The human intestine tissue specific antigen A33 is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. It is expressed in more than 95% of human co- lon cancers, 63% of gastric cancers and 50% of pancreatic cancers, and it has not been found to express in other tissues or cancers. Over the past years, a lot of work has been done on the tissuespecific expression profile, and scientists have identified the promotor and transcription factor （GKLF, CDX1 ） that are associated with specific expression of A33. Advances have been made in the research of monolclonal antibodies for radioimmunotherapy and now the study is in the phase Ⅰ trial in patients with advanced colorectal carcinoma.
作者 张勇 王振宁
机构地区 中国医科大学附属第一医院肿瘤外科 中国医科大学医学基因组教研室
出处 《医学分子生物学杂志》 CAS CSCD 2006年第3期231-233,244,共4页 Journal of Medical Molecular Biology
基金 国家自然科学基金(No.30300342)~~
关键词 A33抗原 跨膜糖蛋白 组织特异性表达 放射免疫治疗 肿瘤 A33 antigen transmembrane glycoprotein tissue-specific expression radioimmunotherapy
分类号 Q786 [生物学—分子生物学]
  • 相关文献

参考文献27

  • 1[1]LIN X P,ALMQVIST N,TELEMO E.Human small intestinal epithelial cells constitutively express the key elements for antigen processing and the production of exosomes[J].Blood Cells Mol Dis,2005,35(2):122-128.
  • 2[2]GARIN-CHESA P,SAKAMOTO J,WELT S,et al.Organ-specific expression of the colon cancer antigen A33,a cell surface target for antibody-based therapy[J].Int J Oncol,1996,19:465-471.
  • 3[3]KOMORI T,YAGI H,NOMURA S,et al.Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts[J].Cell,1997,89 (5):755-764.
  • 4[4]BRAUN T,RUDNICKI M A,ARNOLD H H,et al.Targeted inactivation of the muscle regulatory gene Myf-5 results in abnormal rib development and perinatal death[J].Cell,1992,71 (3):369-382.
  • 5[5]RUDNICKI M A,BRAUN T,HINUMA S,et al.Inactivation of MyoD in mice leads to up-regulation of the myogenic HLH gene Myf-5 and results in apparently normal muscle development[J].Cell,1992,71(3):383-90
  • 6[6]RUDNICKI M A,SCHNEGELSBERG P N,STEAD R H,et al.MyoD or Myf-5 is required for the formation of skeletal muscle[J].Cell,1993,75(7):1351-1359.
  • 7[7]RUDNICKI M A,JAENISCH R.The MyoD family of transcription factors and skeletal myogenesis[J].Bioessays,1995,17 (3):203-209.
  • 8[8]HEATH J K,WHITE S J,JOHNSTONE C N,et al.The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily[J].Proc Natl Acad Sci USA,1997,94(2):469-474.
  • 9[9]KUTACH A K,KADONAGA J T.The downstream promoter element DPE appears to be as widely used as the TATA box in drosophila core promoters[J].Molecul Cell Biol,2000,20 (13):4754-4764.
  • 10[10]JOHNSTONE C N,WHITE S J,TEBBUTT N C,et al.Analysis of the regulation of the A33 antigen gene reveals intestine-specific mechanisms of gene expression[J].J Biol Chem,2002,277(37):34531-34539.

二级参考文献3

共引文献3

医学分子生物学杂志
2006年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部